# Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease

> **NCT02800070** · PHASE1 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 5 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **BIOLOGICAL:** Lentivirus Alpha-gal A transduced stem cells

## Key facts

- **NCT ID:** NCT02800070
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2024-04
- **Final completion:** 2024-04
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2024-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02800070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02800070, "Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02800070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*